Beltran Pedro 4

What Happened

• Pedro Beltran, President, CEO and a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), was granted a derivative award on May 10, 2026 covering 1,103,837 shares. The Form 4 reports the acquisition price as $0.00 and classifies the transaction as an award/grant (transaction code A). This was a grant of an option-like derivative rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-05-10; filing date: 2026-05-12 (Form 4 filed timely).
• Reported consideration: $0.00 (acquisition price reported as zero).
• Shares involved: 1,103,837 derivative shares awarded.
• Shares owned after transaction: not specified in the filing.
• Footnote: F1 — "1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service."
• Filing remark: Exhibit 24 — Power of Attorney.

Context

• This filing records a grant of a derivative award (an option-style award) that vests monthly over 48 months; it is not an immediate sale or exercise. Such grants are commonly part of executive compensation and retention programs. Because no exercise price or immediate sale is reported, there is no realized cash value shown in this Form 4.